Interim analyses of major endpoints will be supplied, in strict confidence, to an independent Data Monitoring and Ethics Committee (DMEC) along with updates on results of other related studies, and any other analyses that the DMEC may request.
Oversight Authorities: Belgium: Federal Agency for Medicines and Health Products, FAMHP
Study Description
Brief Summary: Objective: To compare vNOTES (vaginal Natural Orifice Transluminal Endoscopic Surgery) and established total laparoscopic hysterectomy for successful removal of a non-prolapsed uterus in women due to undergo hysterectomy for benign gynecological pathology.
Study design: Randomized controlled/single center/single-blinded/parallel-group/noninferiority/efficacy trial.
Study population: All women aged 18 to 70 years regardless of parity with a nonprolapsed uterus and a benign indication for hysterectomy.
Randomization: Women will be randomly allocated to undergo one of two techniques for removal of the uterus immediately before surgery by using a computer generated randomization list. We will use stratified randomization according to the estimated uterine size on clinical examination.
Intervention: Women will be treated by a surgeon who is not blinded to the treatment allocation and who is equally skilled in performing both techniques. In the intervention group a vNOTES technique will be used.
Control: In the control group surgery will be done by a classical laparoscopic technique.
Main study parameters/endpoints:
Primary study outcome parameters: successful removal of the womb with the intended approach without conversion to an alternative approach.
Secondary outcomes: the proportion of women admitted to the in-hospital ward for at least one night observation, based on their own preference; postoperative pain scores using a VAS (Visual Analogue Scale) measured between day 1 till 7 by the participating women following surgery and the total amount of analgesics used as described in the standardized pain treatment protocol from day 1 till 7; postoperative infection defined by lower abdominal pain with fever > 38°C and positive clinical signs or laboratory findings; per-or postoperative complications according to the ClavienDindo classification detected during the first six weeks of surgery; hospital readmission within 6 weeks following surgery; duration of the surgical procedure; incidence and intensity of dyspareunia recorded by the participants at baseline, 3 and 6 months by self-reporting using a simple questionnaire and VAS (Visual Analogue Scale); sexual wellbeing recorded by the participants at baseline, 3 and 6 months by SSFS (Short Sexual Functioning Scale); health-related quality of life, at baseline, at 3 and 6 months by self-reporting the EQ-5D scale; direct and indirect costs incurred up to 6 weeks after the hysterectomy associated with both procedures.
NOTE : Brief Summary should have no more than 2500 characters. • Do more women treated by vNOTES prefer to leave the day care unit on the day of surgery compared to LSC? • Do women treated by vNOTES suffer from less pain compared to women treated by LSC in the first postoperative week? • Is the removal of a uterus by vNOTES faster compared to LSC? • Does a vNOTES cause more pelvic infection or other complications compared to LSC? • Does a vNOTES result in more hospital readmissions within 6 weeks after surgery compared to LSC? • Does a vNOTES approach result in more women reporting dyspareunia, less sexual wellbeing or less health-related quality of life at 3 or 6 months after surgery when compared to women treated by LSC? • What are the direct and indirect costs up to 6 weeks after the surgical intervention of a vNOTES compared to LSC? 2. TRIAL DESIGN 2.1. Design A single center, single-blinded, parallel group randomized, non-inferiority efficacy trial.
2.2. Simple pilot randomized trial. 2.3. Time schedule Based upon the mean number of hysterectomies performed annually for benign gynecological disease at the department of Obstetrics and Gynecology of the participating center (168) the investigators estimate that the duration of recruitment will be 12 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2 years.
Participating center Department of Obstetrics and Gynecology
Imeldahospital Imeldalaan 9 2820 Bonheiden Belgium 3. ELIGIBILITY, CONSENT AND RANDOMIZATION 3.1. Screening and consent prior to surgery All women aged 18 to 70 years, regardless of parity, with a nonprolapsed uterus in need of a hysterectomy for benign indication are eligible for inclusion.
3.2. Determining eligibility All women aged 18 to 70 years, regardless of parity, with a non-prolapsed uterus in need of a hysterectomy for benign indication who provide consent to participation are eligible in the HALON trial and will be randomized before the procedure.
3.3. Randomization If the woman is eligible for the HALON trial, the trial secretary will obtain a randomized allocation the day before surgery. This will be done using a randomization list generated by a free computer software program offered by Research Randomizer (https://www.randomizer.org). The random sequence generation will be concealed using sequentially numbered opaque sealed envelopes. The envelope will be opened by the nurse assistant the day before surgery for practical logistic reasons.
3.4. Patients with strong preference for treatment A minority of women will express a clear preference for one of both treatments (e.g. strong desire to have no scar) and for this reason will not wish to be randomized between surgical treatments. To investigate how outcomes vary by choice, these women could be followed up in exactly the same way as for those women randomized into the HALON trial. A formal non-randomized follow-up of these women will not be done for logistical reasons.
3.5. Stratification of randomization A blocked randomization procedure will be used to avoid chance imbalances for the parameter 'uterine size'. 4. TREATMENT ALLOCATIONS 4.1. Surgical procedures The principal investigator, who has training and experience in both laparoscopy and NOTES, will perform all surgical procedures. He is therefore not blinded. All vNOTES participants will be blinded by three superficial non-therapeutic or "mock" skin incisions similar to those done with the laparoscopic technique.
4.1.1 vNOTES hysterectomy This is the surgical procedure done in the intervention arm of the HALON trial. 4.1.2 LSC hysterectomy This is the surgical procedure done in the control arm of the HALON trial. 5. FOLLOW-UP AND OUTCOME MEASURES 5.1. Clinical assessments 5.1.1
Format PROMs (Patient reported outcomes) will be collected using a postal questionnaire, which will include a combination of disease specific (Pain on sexual intercourse measured by VAS scale and SSFS Scale) and generic measurement instruments (EQ-5D).
The postal questionnaires will be sent from the HALON Trial Office with postage paid envelopes two weeks before the due date. Reminders will be sent to patients if the questionnaire is not returned within one week of the due date and attempts will be made to contact the patient by phone if the questionnaire is not returned by two weeks after the due date.
Timing of assessments
The primary outcome will be measured clinically at the end of the surgical procedure. In addition PROMs will take place at baseline (pain on sexual intercourse, health-related quality of life and sexual well being), the evening of the surgical intervention (in-hospital admission), during the first postoperative week (pain by VAS scores and analgetic drugs) and at 3 and 6 months (dyspareunia/ sexual well being/health related quality of life). Clinical physician assessment will take place the evening of the surgical intervention (in-hospital admission) and during the first six weeks following surgery (pelvic infection, surgical complications, hospital readmission rate).
Primary clinical outcome measure
The proportion of women successfully treated by removing the uterus by the intended approach without conversion to another approach, using a dichotomous outcome measure, will be used as a measure of efficacy.
Secondary clinical outcome measures
The following secondary outcomes will be measured:
• The proportion of women addmitted in-hospital for at least one night observation based on their own preference, as a dichotomous outcome.
• Postoperative pain scores, as an ordinal outcome, measured using a VAS (Visual Analogue Scale) twice daily from day 1 till 7 self-reported by the participating women. • Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.
• Postoperative infection as a dichotomous outcome.
• Per-or postoperative complications according to the Clavien-Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome.
• The proportion of women readmitted to hospital within 6 weeks following surgery.
• Incidence and intensity of dyspareunia recorded by the participants at baseline, 3 and 6 months by self-reporting using a simple questionnaire and VAS scale, as a dichotomous and ordinal outcome.
• Sexual wellbeing at baseline, at 3 and 6 months by self-reporting the SSFS (Short Sexual Functioning Scale).
• Health related quality of life, at baseline, at 3 and 6 months by self-reporting the EQ-5D scale.
• Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/abdominal wound closure, as a continuous outcome. 5.4.The direct costs up to 6 weeks after the hysterectomy of the vNOTES technique compared to LSC. 6. ACCRUAL AND ANALYSIS 6.1. Sample size The sample size for the primary outcome of this trial has been chosen to give good statistical power to preclude any clinically important inferiority of vNOTES compared to laparoscopy and is based on evidence retrieved from a Dutch prospective cohort study. Based on the power calculations for the primary outcome and assuming a loss-to-follow-up rate of 15% we decided to include 66 study participants in the HALON trial.
6.2. Projected accrual and attrition rates Based upon the mean number of hysterectomies performed annually at the department of Obstetrics and Gynecology of the participating center (168) the investigators anticipate that the duration of recruitment will be 12 months. Based upon the follow up (6 months) and the period of analysis/ reporting (3 months) the total study period will be 2 years. First publication will be possible within four years of trial commencement.
The sample size calculations have allowed for a 15% loss to follow up rate. In order to minimize rates of attrition a dedicated research secretary will be amployed to optimize recruitment and follow up. The proportion of women addmitted in-hospital for at least one night observation based on their own preference after discharge from the day care unit, as a dichotomous outcome. The decision to discharge or to admit to hospital for the night will be based solely on the choice of the woman to return home the same day or stay overnight. 
